← Leaderboards
Keith August
University Of Kansas Lawrence
$452,897
Attributed
$905,793
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $364.9K · FY2019–22$500K$375K$250K$125K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$905,793 · 1
By mechanism
R33$905,793 · 1
Top collaborators
- Steven A. Soper4 shared
Others in their field
Other Emerging Leaders on “Acute Lymphocytic Leukemia”
- Crystal Mackall · Children'S Hosp Of Philadelphia$12,361,966
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$8,557,384
- Adam De Smith · University Of Southern California$5,277,579
- Karen R Rabin · Baylor College Of Medicine$4,946,686
- Ernesto Guccione · Icahn School Of Medicine At Mount Sinai$4,876,508
Research focus
Acute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAdult Acute Myeloblastic LeukemiaAffectAffinityAgedAntibodiesAntigensAspirate SubstanceBaseBloodBlood CellsBone MarrowBone Marrow BiopsyBone Marrow CytometryCancer CellCause Of DeathCd19 GeneCd34 GeneCd7 GeneCell CountCell LineCell ModelAcute Leukemia
Grant awards (4)
Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia$245,275
R33 · FY2022 · CA
Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia$54,028
R33 · FY2021 · CA
Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia$364,903
R33 · FY2020 · CA
Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia$241,587
R33 · FY2019 · CA